Travere Therapeutics Director Executes Planned Stock Sale Amid Recent Market Rally
A recent SEC Form 4 filing reveals that Roy D. Baynes, a director at Travere Therapeutics, Inc. (NASDAQ:TVTX), completed a significant sale of company shares on May 1, 2026. The transaction, which involved the disposal of 9,750 shares of common stock, was conducted under a Rule 10b5-1(c) trading plan established in late 2025. This activity occurs w…